Duplication method of rat continuous hyperuricemia model

A technology of hyperuricemia and model, which can be used in medical preparations containing active ingredients, pharmaceutical formulations, organic active ingredients, etc., can solve problems such as abnormality, and achieve good application prospects and clinical significance.

Inactive Publication Date: 2018-05-15
CHINA PHARM UNIV
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, common clinical drugs for the treatment of hyperuricemia, such as allopurinol, febuxostat, benzbromarone,

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Duplication method of rat continuous hyperuricemia model
  • Duplication method of rat continuous hyperuricemia model

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] Embodiment 1: The specific steps of the specific construction of hyperuricemia model in this embodiment are as follows

[0015] 1) Animal selection and model construction: Select 8-week-old male clean-grade SD rats, weighing 180-220g, provided by Shanghai Xipuer-Bikay Experimental Materials Co., Ltd., and bred in the clean-grade animal breeding room of China Pharmaceutical University. During the period, the room temperature was controlled at about 22±2°C, the humidity was controlled at about 55±5°C, the lighting was alternated 12h / 12h, and the rats were free to eat and drink water to observe the changes in the body characteristics of the rats, and 20 SD rats with normal body characteristics were selected for modeling experiment.

[0016] 2) Materials and equipment:

[0017] Potassium oxonate (CAS: 2207-75-2) was purchased from Shanghai Shifeng Biotechnology Co., Ltd., D-fructose (CAS: 57-4-7) was purchased from Biosharp Company; uric acid assay kit was purchased from N...

Embodiment 2

[0019] Embodiment 2: This embodiment uses the animal intervention of Embodiment 1 to carry out the experiment. At the end of the third week of the animal experiment, the rats were fasted for 12 hours and then sacrificed. After the sacrifice, the abdominal cavity was quickly opened, the right kidney was removed, and placed in 4% paraformaldehyde Fixed in the solution, routinely embedded in paraffin, made 3 μm thick sections for HE staining, and observed under a light microscope (×200); the results are shown in the attached figure, the blank control group was glomeruli and renal tubules with normal structure, Glomeruli were normal in size and evenly distributed, and there was no swelling and degeneration of renal tubules. A certain degree of cytoplasmic separation appeared in the renal tubules of the fructose control group. Obvious vacuoles appeared in the renal tubules of the oxonate potassium control group. In the oxonate potassium fructose group, glomerular atrophy and degen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of experimental model building, and relates to a duplication method of a rat continuous hyperuricemia model. The method comprises the following four steps:animal selection, adaptive feeding, model building and model application; the method comprises the following specific steps: performing adaptive feeding on selected healthy rats in a clean animal feeding room for 1 week, and ensuring that rats with normal morphological characteristics are used for building a model; and injecting 500 mg.kg<-1> uricase inhibitor oteracil potassium to the rats withnormal morphological characteristics at room temperature every day in an intraperitoneal injection administration manner, and meanwhile giving 10 percent fructose drinking water and sufficient diet for 24 hours without interruption. Administration to rats and molding are continuously performed every day, and administration is continued for 3 weeks, a sample rat hyperuricemia model is obtained; andthe built rat hyperuricemia model is applied, so that a hypeluricemia model with typical disease characteristics is obtained. The method is simple to operate, and short in duplication cycle, can ensure that the hyperuricemia level of the rats can be obviously improved, can further properly simulate the clinical features of hyperuricemia, and has a good application prospect.

Description

1. Technical field [0001] The invention belongs to the technical field of experimental model construction, and relates to a method capable of constructing a long-term stable rat hyperuricemia model. 2. Background technology [0002] Hyperuricemia is a typical disease caused by purine metabolism disorder or decreased excretion of uric acid. It is characterized by the concentration of uric acid, the end product of purine metabolism, in the body 2-8 times higher than the normal level and maintained for a long time. Epidemiological studies have shown that when the blood uric acid concentration in the body continues to be high for a long time, it will cause gout, kidney disease, high blood pressure and diabetes. However, common clinical drugs for the treatment of hyperuricemia, such as allopurinol, febuxostat, benzbromarone, etc., will cause adverse reactions such as skin allergies, diarrhea, and abnormal liver function in varying degrees. Therefore, it is very important to find...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7004A61K31/53A61P19/06
CPCA61K31/7004A61K31/53A61K2300/00
Inventor 陈君胡学文黄碧霞
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products